カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

神経血管デバイスの世界市場予測（～2028）：病態別、エンドユーザー別、地域別

◆英語タイトル：Neurovascular Devices Market by Disease Pathology (Cerebral Ameurysm (Embolic coils), Ischemic Stroke (Clot retrievers, Aspiration, Microcatheters), AVM (Liquid Embolic Agents)), End User (Hospitals), & Region - Global Forecast to 2028
	◆商品コード：MD1310-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年5月4日 ◆ページ数：255 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

マーケッツアンドマーケッツ社では、世界の神経血管デバイス市場規模が2023年36億ドルから2028年55億ドルまで、予測期間中、年平均8.7%成長すると予測しています。当調査資料では、神経血管デバイスの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、病態別（脳動脈瘤、虚血性脳卒中、頸動脈狭窄症、動静脈奇形・瘻孔、その他）分析、エンドユーザー別（病院＆外科手術センター、外来診療センター、研究所＆学術機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況、隣接/関連市場などの項目を掲載しています。なお、当書に掲載されている企業情報には、Stryker (US)、Johnson & Johnson (US)、Medtronic (Ireland)、Terumo Corporation (Japan)、Penumbra, Inc. (US)、MicroPort Scientific Corporation (China)、Kaneka Corporation (Japan)、BALT (France)、Perflow Medical Ltd. (Israel)、Phenox GmbH (Germany)、Sensome (France)、Evasc (Canada)、Rapid Medical (Israel)、Asahi Intecc Co., Ltd (Japan)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の神経血管デバイス市場規模：病態別
　 - 脳動脈瘤における市場規模
　 - 虚血性脳卒中における市場規模
　 - 頸動脈狭窄症における市場規模
　 - 動静脈奇形・瘻孔における市場規模
　 - その他病態における市場規模
・世界の神経血管デバイス市場規模：エンドユーザー別
　 - 病院＆外科手術センターにおける市場規模
　 - 外来診療センターにおける市場規模
　 - 研究所＆学術機関における市場規模
・世界の神経血管デバイス市場規模：地域別
　 - 北米の神経血管デバイス市場規模
　 - ヨーロッパの神経血管デバイス市場規模
　 - アジア太平洋の神経血管デバイス市場規模
　 - 中南米の神経血管デバイス市場規模
　 - 中東/アフリカの神経血管デバイス市場規模
・競争状況
・企業情報

“世界の神経血管デバイス市場は、2023年の36億米ドルから2028年には55億米ドルに達すると予測され、予測期間中の年平均成長率は8.7%と展望”
神経血管デバイス市場の需要増加は、高血圧、糖尿病、肥満の有病率の増加により、虚血性脳卒中、脳動脈瘤などの様々な神経血管疾患を発症するリスクのある人口比率が増加していることが背景にあります。しかし、神経介入手技や関連製品のコストが高いこと、新興国では熟練した神経科医が不足していることが、市場の成長を妨げる要因となっています。

“予測期間中のCAGRは虚血性脳卒中分野が最も高い”
疾患病態に基づき、神経血管デバイス市場は、脳動脈瘤、虚血性脳卒中、頸動脈狭窄症、動静脈奇形・瘻孔、その他の疾患病態（海綿体奇形、もやもや病を含む）に区分されます。虚血性脳卒中発症率の増加と機械的血栓除去術の増加により、虚血性脳卒中分野の年平均成長率は上昇します。

“予測期間中、エンドユーザー別の神経血管デバイス市場において、病院・手術センターセグメントが最大の市場シェアを占める”
エンドユーザーに基づき、神経血管デバイス市場は、病院＆外科センター、外来ケアセンター、研究所・学術機関に区分されます。予測期間中、神経血管機器市場で最大のシェアを獲得したのは病院・外科センターで、これは対象患者の入院増加、神経血管手術件数の増加、発展途上国の病院インフラのアップグレードに加え、これらの環境で技術的に進歩した神経血管デバイスが利用可能になったことに起因しています。

“予測期間中、地域別の神経血管デバイス市場で最も高い市場シェアを占めたのは北米セグメント”
地域別に見ると、世界の神経血管デバイス市場は、北米、欧州、アジア太平洋、中南米、中東・アフリカに分類されます。北米は予測期間中に高い市場シェアが見込まれます。これは、虚血性脳卒中、脳動脈瘤、動静脈奇形に対する血管内治療手技の強力な採用、新規神経血管デバイス開発のためのR&D投資の利用可能性、地域における主要企業の強力な足場、神経血管治療手技に対する有利な償還政策などの要因によるものです。

供給側の一次インタビューの内訳（企業タイプ別、役職別、地域別）
– 企業タイプ別 Tier1（30%）、Tier2（45%）、Tier3（25%）
– 役職別 Cレベル(20%)、ディレクターレベル(20%)、その他(45%)
– 地域別北米(40%)、アジア太平洋(30%)、欧州(20%)、中南米(7%)、中東・アフリカ(3%)

主要企業：Stryker（米国）、Johnson & Johnson （米国）、Medtronic（アイルランド）、Terumo（日本）、Penumbra, Inc. Ltd.（イスラエル）、Phenox GmbH（ドイツ）、Sensome（フランス）、Evasc（カナダ）、Rapid Medical（イスラエル）、Asahi Intecc Co., Ltd（日本）、Acandis GmbH（ドイツ）、Medikit Co. Ltd.（日本）、Imperative Care Co. (日本）、Imperative Care（米国）、Lepu Medical Technology(Beijing)Co. Ltd.（中国）、Cerus Endovascular Inc.（米国）、Zylox-Tonbridge Medical Co.（中国）

調査範囲
この調査レポートは、神経血管デバイス市場を疾患病態別（脳動脈瘤、虚血性脳卒中、頸動脈狭窄症、動静脈奇形・瘻孔、その他の疾患病態）、エンドユーザー別（病院・手術センター、外来医療センター、研究所・学術機関）、地域別（北米、欧州、アジア太平洋地域、中南米、中東・アフリカ）に分類しています。神経血管デバイス市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、協定、新製品・サービスの発表、M&A、神経血管デバイス市場に関連する最近の動向に関する洞察を提供します。神経血管デバイス市場のエコシステムにおける今後の新興企業の競合分析も本レポートでカバーしています。

レポート購入の主な利点
本レポートは、神経血管デバイス市場全体およびサブセグメントについて収益の近似値に関する情報を提供することで、本市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社の事業をより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、当レポートは、関係者が市場動向を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：
– 神経血管デバイス市場の成長に影響を与える主要な促進要因（神経血管疾患の発生率上昇、神経血管処置の増加、医療償還の利用可能性、新興国全体での医療インフラの拡大）、抑制要因（神経血管処置および関連装置の高コスト、新興国における熟練神経外科医の不足）、機会（低侵襲神経外科処置の選好の増加、神経血管治療におけるR&D活動の活発化）、課題（神経血管処置装置の厳しい規制承認プロセス）分析
– 製品開発／イノベーション：神経血管デバイス市場における今後の技術、研究開発活動、新製品・サービスの発売に関する詳細な洞察
– 市場開発：有利な市場に関する包括的な情報 – 当レポートでは、さまざまな地域の神経血管デバイス市場を分析
– 市場の多様化：神経血管デバイス市場における新製品、未開拓地域、最近の開発、投資に関する詳細情報
– 競合評価： Stryker（米国）、Johnson & Johnson （米国）、Medtronic（アイルランド）、Terumo（日本）、Penumbra, Inc. Ltd.（イスラエル）

❖ レポートの目次 ❖

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 STUDY SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 GEOGRAPHIC SCOPE 34
1.3.3 YEARS CONSIDERED 34
1.4 CURRENCY CONSIDERED 34
1.5 MARKET STAKEHOLDERS 35
1.6 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 1 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY RESEARCH 39
2.1.2.1 Key data from primary sources 39
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 40
FIGURE 3 NEUROVASCULAR DEVICES MARKET: BREAKDOWN OF PRIMARIES 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 41
2.2.1 PRODUCT-BASED MARKET ESTIMATION 42
2.2.2 VOLUME-BASED MARKET ESTIMATION 42
FIGURE 5 MARKET SIZE ESTIMATION: NEUROVASCULAR DEVICES MARKET 43
2.2.3 PRIMARY RESEARCH VALIDATION 43
2.3 DATA TRIANGULATION 44
FIGURE 6 DATA TRIANGULATION METHODOLOGY 44
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 45
2.4.1 RESEARCH ASSUMPTIONS 45
2.4.2 RESEARCH LIMITATIONS 45
2.5 RECESSION IMPACT 46
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH) 46
3 EXECUTIVE SUMMARY 47
FIGURE 7 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION) 47
FIGURE 8 HOSPITALS AND SURGICAL CENTERS SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 48
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD 49
4 PREMIUM INSIGHTS 50
4.1 NEUROVASCULAR DEVICES MARKET OVERVIEW 50
FIGURE 10 AN INCREASE IN THE NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS BRAIN/ CEREBRAL ANEURYSMS, STROKES, AND EPILEPSY, IS EXPECTED TO DRIVE THE MARKET GROWTH. 50
4.2 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION) 51
FIGURE 11 CEREBRAL ANEURYSMS TO DOMINATE NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD 51
4.3 NEUROVASCULAR DEVICES MARKET, BY REGION AND DISEASE PATHOLOGY (2022) 52
FIGURE 12 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE IN US 52
4.4 NEUROVASCULAR DEVICES MARKET, BY COUNTRY 53
FIGURE 13 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 14 NEUROVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Rising incidence of neurovascular diseases 55
FIGURE 15 PROPORTION OF GERIATRIC TO TOTAL WORLD POPULATION, BY COUNTRY, 2020 VS. 2030 (MILLION PEOPLE) 56
5.2.1.2 Availability of medical reimbursements for neurovascular procedures 56
TABLE 2 US: REIMBURSEMENT FOR INTERVENTIONAL NEUROLOGY PROCEDURES 57
5.2.1.3 Expansion of healthcare infrastructure across emerging economies 57
5.2.1.4 Rising demand for effective neurovascular therapies 58
5.2.2 RESTRAINTS 58
5.2.2.1 Shortage of skilled neurosurgeons 58
5.2.2.2 High procedural cost of neurovascular surgeries and associated products 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Rising R&D activities for neurovascular therapies 59
5.2.3.2 Growing preference for minimally invasive neurosurgical procedures 60
5.2.4 CHALLENGES 60
5.2.4.1 Stringent regulatory approval process for medical devices 60
5.3 SUPPLY CHAIN ANALYSIS 62
FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS 62
5.4 VALUE CHAIN ANALYSIS 63
FIGURE 17 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED THROUGH REGULATION & DISTRIBUTION STAGES 63
5.5 PORTER’S FIVE FORCES ANALYSIS 63
5.5.1 OVERVIEW 63
TABLE 3 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 64
5.5.2 THREAT OF NEW ENTRANTS 64
5.5.3 THREAT OF SUBSTITUTES 64
5.5.4 BARGAINING POWER OF SUPPLIERS 64
5.5.5 BARGAINING POWER OF BUYERS 65
5.5.6 INTENSITY OF COMPETITIVE RIVALRY 65
5.6 REGULATORY LANDSCAPE 65
5.6.1 NORTH AMERICA 65
5.6.1.1 US 65
TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION 66
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
5.6.1.2 Canada 67
5.6.2 EUROPE 67
5.6.3 ASIA PACIFIC 67
5.6.3.1 China 67
5.6.3.2 Japan 68
5.6.3.3 India 68
5.6.3.4 South Korea 68
5.7 REIMBURSEMENT SCENARIO 69
TABLE 6 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES (2021) 69
5.8 PRICING TREND ANALYSIS 72
5.8.1 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY KEY PLAYER, 2021 (USD) 72
5.8.2 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY REGION/COUNTRY, 2021 (USD) 73
5.9 PATENT ANALYSIS 74
FIGURE 18 TOP PATENT APPLICANTS FOR ORTHOPEDIC DEVICES, JANUARY 2012–MARCH 2023 74
5.10 TRADE ANALYSIS 75
TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2017–2021 (USD MILLION) 75
TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION) 75
5.11 ECOSYSTEM MAP 76
5.12 CASE STUDY ANALYSIS 76
5.12.1 STENT-ASSISTED COILING (SAC) THERAPY FOR INTRACRANIAL ANEURYSMS 76
TABLE 9 USAGE OF INTRACRANIAL STENTS FOR TREATMENT OF BROAD-NECKED INTRACRANIAL ANEURYSMS 76
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023 77
TABLE 10 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 77
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.14 STAKEHOLDERS AND BUYING CRITERIA 79
5.14.1 KEY STAKEHOLDERS 79
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS 79
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATION SEGMENTS (%) 79
5.15 KEY BUYING CRITERIA 80
FIGURE 21 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES 80
TABLE 12 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES 80
6 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY 81
6.1 INTRODUCTION 82
TABLE 13 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 82
TABLE 14 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 15 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 83
6.2 CEREBRAL ANEURYSMS 83
TABLE 16 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 84
TABLE 17 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 18 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY END USER, 2021–2028 (USD MILLION) 85
6.2.1 EMBOLIC COILS 85
TABLE 19 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 20 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 86
6.2.1.1 Bare detachable coils 86
6.2.1.1.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth 86
TABLE 21 CEREBRAL ANEURYSMS MARKET FOR BARE DETACHABLE COILS, BY REGION, 2021–2028 (USD MILLION) 87
6.2.1.2 Coated detachable coils 87
6.2.1.2.1 High cost of coated detachable coils to limit adoption 87
TABLE 22 CEREBRAL ANEURYSMS MARKET FOR COATED DETACHABLE COILS, BY REGION, 2021–2028 (USD MILLION) 88
6.2.2 FLOW DIVERSION DEVICES 88
6.2.2.1 Rising R&D activities to develop novel flow diversion devices to promote growth 88
TABLE 23 CEREBRAL ANEURYSMS MARKET FOR FLOW DIVERSION DEVICES, BY REGION, 2021–2028 (USD MILLION) 89
6.2.3 INTRACRANIAL STENTS 89
6.2.3.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption 89
TABLE 24 CEREBRAL ANEURYSMS MARKET FOR INTRACRANIAL STENTS, BY REGION, 2021–2028 (USD MILLION) 89
6.2.4 MICROCATHETERS 90
6.2.4.1 Growing number of neurovascular procedures and favorable reimbursement scenarios to boost demand 90
TABLE 25 CEREBRAL ANEURYSMS MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION) 90
6.2.5 GUIDEWIRES 90
6.2.5.1 Growing utilization of nitinol guidewires for cerebral aneurysm procedures to boost growth 90
TABLE 26 CEREBRAL ANEURYSMS MARKET FOR GUIDEWIRES, BY REGION, 2021–2028 (USD MILLION) 91
6.3 ISCHEMIC STROKES 91
TABLE 27 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 28 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE 2021–2028 (USD MILLION) 92
TABLE 29 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY END USER, 2021–2028 (USD MILLION 93
6.3.1 CLOT RETRIEVER DEVICES 93
6.3.1.1 Growing number of clinical trials for development of novel clot retriever stents to drive market 93
TABLE 30 ISCHEMIC STROKES MARKET FOR CLOT RETRIEVER DEVICES, BY REGION, 2021–2028 (USD MILLION) 94
6.3.2 SUCTION & ASPIRATION DEVICES 94
6.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market 94
TABLE 31 ISCHEMIC STROKES MARKET FOR SUCTION & ASPIRATION DEVICES, BY REGION, 2021–2028 (USD MILLION) 95
6.3.3 VASCULAR SNARES 95
6.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares 95
TABLE 32 ISCHEMIC STROKES MARKET FOR VASCULAR SNARES, BY REGION, 2021–2028 (USD MILLION) 95
6.3.4 MICROCATHETERS 96
6.3.4.1 High demand for minimally invasive treatment in ischemic strokes to boost adoption of microcatheters 96
TABLE 33 ISCHEMIC STROKES MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION) 96
6.3.5 MICROGUIDEWIRES 96
6.3.5.1 Increasing innovations in guidewires to promote growth 96
TABLE 34 ISCHEMIC STROKES MARKET FOR MICROGUIDEWIRES, BY REGION, 2021–2028 (USD MILLION) 97
6.3.6 BALLOON CATHETERS 97
6.3.6.1 Growing recognition of benefits associated with balloon catheters to bolster demand 97
TABLE 35 ISCHEMIC STROKES MARKET FOR BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION) 98
6.4 CAROTID ARTERY STENOSIS 98
TABLE 36 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS CAROTID ARTERY STENOSIS, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 37 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 99
TABLE 38 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY END USER, 2021–2028 (USD MILLION) 99
6.4.1 CAROTID ARTERY STENTS 99
6.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth 99
TABLE 39 CAROTID ARTERY STENOSIS MARKET FOR CAROTID ARTERY STENTS, BY REGION, 2021–2028 (USD MILLION) 100
6.4.2 EMBOLIC PROTECTION DEVICES 101
6.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth 101
TABLE 40 CAROTID ARTERY STENOSIS MARKET FOR EMBOLIC PROTECTION DEVICES, BY REGION, 2021–2028 (USD MILLION) 101
6.4.3 BALLOON CATHETERS 102
6.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth 102
TABLE 41 CAROTID ARTERY STENOSIS MARKET FOR BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION) 102
6.5 ARTERIOVENOUS MALFORMATION & FISTULAS 102
TABLE 42 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 43 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 103
TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY END USER, 2021–2028 (USD MILLION) 103
6.5.1 LIQUID EMBOLIC AGENTS 104
6.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth 104
TABLE 45 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2021–2028 (USD MILLION) 104
6.5.2 OCCLUSION BALLOON CATHETERS 104
6.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth 104
TABLE 46 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR OCCLUSION BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION) 105
6.5.3 MICROCATHETERS 105
6.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand 105
TABLE 47 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION) 105
6.6 OTHER DISEASE PATHOLOGIES 106
TABLE 48 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 49 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY END USER, 2021–2028 (USD MILLION) 106
7 NEUROVASCULAR DEVICES MARKET, BY END USER 107
7.1 INTRODUCTION 108
TABLE 50 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 108
7.2 HOSPITALS AND SURGICAL CENTERS 108
7.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET 108
TABLE 51 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021–2028 (USD MILLION) 109
7.3 AMBULATORY CARE CENTERS 109
7.3.1 OPERATIONAL AND ECONOMIC BENEFITS OFFERED BY ACCS TO DRIVE MARKET 109
TABLE 52 NEUROVASCULAR DEVICES MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 110
7.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 110
7.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH 110
TABLE 53 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 111
8 NEUROVASCULAR DEVICES MARKET, BY REGION 112
8.1 INTRODUCTION 113
TABLE 54 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 113
8.2 NORTH AMERICA 113
8.2.1 NORTH AMERICA: RECESSION IMPACT 114
FIGURE 22 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT 115
TABLE 55 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 56 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 116
TABLE 57 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 58 NORTH AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 59 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 60 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 61 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 62 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 118
8.2.2 US 118
8.2.2.1 Presence of established neurovascular device manufacturers to drive market 118
TABLE 63 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 119
TABLE 64 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 65 US: EMBOLIC COILS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 66 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 67 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 68 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 121
8.2.3 CANADA 121
8.2.3.1 Large target pool for ischemic stroke patients to drive market 121
TABLE 69 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 122
TABLE 70 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 71 CANADA: EMBOLIC COILS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 72 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 73 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 74 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 123
8.3 EUROPE 124
8.3.1 EUROPE: RECESSION IMPACT 124
TABLE 75 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 125
TABLE 76 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 77 EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 78 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 79 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 80 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 81 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 127
8.3.2 GERMANY 127
8.3.2.1 Increasing adoption of endovascular coils and stents to drive market 127
TABLE 82 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 128
TABLE 83 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 84 GERMANY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 85 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 86 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 87 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 130
8.3.3 FRANCE 130
8.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market 130
TABLE 88 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 131
TABLE 89 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 90 FRANCE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 91 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 92 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 93 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 133
8.3.4 UK 133
8.3.4.1 Rising government initiatives to increase accessibility of neurovascular procedures to drive market 133
TABLE 94 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 134
TABLE 95 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 96 UK: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 97 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 98 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 99 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 136
8.3.5 ITALY 136
8.3.5.1 Increasing thrombectomy treatment rates to drive demand for neurovascular devices 136
TABLE 100 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 137
TABLE 101 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 102 ITALY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 103 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 104 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 105 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 139
8.3.6 SPAIN 139
8.3.6.1 Rising number of clinical trials for interventional neurovascular procedures to support market growth 139
TABLE 106 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 140
TABLE 107 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 108 SPAIN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 109 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 110 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 111 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 142
8.3.7 REST OF EUROPE 142
TABLE 112 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 143
TABLE 113 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 114 REST OF EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 115 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 116 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 117 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 145
8.4 ASIA PACIFIC 145
8.4.1 ASIA PACIFIC: RECESSION IMPACT 146
TABLE 118 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 119 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 147
TABLE 120 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 121 ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 122 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 123 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 124 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 125 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 149
FIGURE 23 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT 150
8.4.2 JAPAN 151
8.4.2.1 Favorable reimbursement policy for adoption of neurovascular procedures to drive market 151
TABLE 126 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 151
TABLE 127 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 128 JAPAN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 129 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 130 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 131 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 153
8.4.3 CHINA 153
8.4.3.1 Robust presence of neurovascular device manufacturers to drive market 153
TABLE 132 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 154
TABLE 133 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 134 CHINA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 135 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 136 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 137 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 156
8.4.4 INDIA 156
8.4.4.1 Supportive government initiatives to drive uptake for neurovascular devices 156
TABLE 138 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 157
TABLE 139 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 140 INDIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 141 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 142 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 143 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 159
8.4.5 AUSTRALIA 159
8.4.5.1 Rising incidence of cerebrovascular disease to drive market 159
TABLE 144 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 160
TABLE 145 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 146 AUSTRALIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 147 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 148 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 149 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 162
8.4.6 SOUTH KOREA 162
8.4.6.1 Health insurance coverage for neurovascular procedures to support market growth 162
TABLE 150 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 163
TABLE 151 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 152 SOUTH KOREA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 153 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 154 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 155 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 165
8.4.7 REST OF ASIA PACIFIC 165
TABLE 156 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 165
TABLE 157 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 158 REST OF ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 159 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 160 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 161 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 167
8.5 LATIN AMERICA 167
8.5.1 LATIN AMERICA: RECESSION IMPACT 167
TABLE 162 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 168
TABLE 163 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 164 LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 165 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 166 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 167 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 168 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 170
8.5.2 BRAZIL 170
8.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market 170
TABLE 169 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 171
TABLE 170 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 171 BRAZIL: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 172 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 173 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 174 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 173
8.5.3 MEXICO 173
8.5.3.1 Increasing incidence of neurovascular diseases to support market growth 173
TABLE 175 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 174
TABLE 176 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 177 MEXICO: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 178 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 179 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 180 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 176
8.5.4 REST OF LATIN AMERICA 176
TABLE 181 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 176
TABLE 182 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 183 REST OF LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 184 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 185 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 186 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 178
8.6 MIDDLE EAST & AFRICA 178
8.6.1 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH 178
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 179
TABLE 187 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 188 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION) 180
TABLE 189 MIDDLE EAST & AFRICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 190 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 191 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 192 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS & FISTULAS, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 193 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 182
9 COMPETITIVE LANDSCAPE 183
9.1 INTRODUCTION 183
9.1.1 STRATEGIES ADOPTED BY KEY PLAYERS 183
FIGURE 24 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS (2019−2023) 184
9.2 REVENUE SHARE ANALYSIS 185
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN NEUROVASCULAR DEVICES MARKET 185
9.3 MARKET SHARE ANALYSIS 185
FIGURE 26 NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER (2022) 186
9.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2022) 187
9.4.1 STARS 187
9.4.2 EMERGING LEADERS 187
9.4.3 PERVASIVE PLAYERS 187
9.4.4 PARTICIPANTS 187
FIGURE 27 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2021) 188
9.5 COMPETITIVE LEADERSHIP MAPPING: STARTUPS/SME EVALUATION QUADRANT (2022) 189
9.5.1 PROGRESSIVE COMPANIES 189
9.5.2 RESPONSIVE COMPANIES 189
9.5.3 DYNAMIC COMPANIES 189
9.5.4 STARTING BLOCKS 189
FIGURE 28 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/STARTUPS (2022) 190
9.6 NEUROVASCULAR DEVICES MARKET: FOOTPRINT ANALYSIS OF LEADING PLAYERS 191
TABLE 194 COMPANY FOOTPRINT ANALYSIS 191
TABLE 195 PRODUCT FOOTPRINT 192
TABLE 196 REGIONAL FOOTPRINT 193
9.6.1 PRODUCT LAUNCHES & APPROVALS 194
TABLE 197 NEUROVASCULAR DEVICES MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2019–MARCH 2023) 194
9.6.2 DEALS 194
TABLE 198 NEUROVASCULAR DEVICES MARKET: KEY DEALS (JANUARY 2019–MARCH 2023) 194
9.6.3 OTHER DEVELOPMENTS 195
TABLE 199 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–MARCH 2023) 195

10 COMPANY PROFILES 196
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
10.1 KEY PLAYERS 196
10.1.1 STRYKER 196
TABLE 200 STRYKER: BUSINESS OVERVIEW 196
FIGURE 29 STRYKER: COMPANY SNAPSHOT (2022) 197
10.1.2 MEDTRONIC 201
TABLE 201 MEDTRONIC: BUSINESS OVERVIEW 201
FIGURE 30 MEDTRONIC: COMPANY SNAPSHOT (2022) 202
10.1.3 JOHNSON & JOHNSON 206
TABLE 202 JOHNSON & JOHNSON: BUSINESS OVERVIEW 206
FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022) 207
10.1.4 TERUMO CORPORATION 210
TABLE 203 TERUMO CORPORATION: BUSINESS OVERVIEW 210
FIGURE 32 TERUMO CORPORATION: COMPANY SNAPSHOT (2021) 211
10.1.5 PENUMBRA, INC. 214
TABLE 204 PENUMBRA, INC.: BUSINESS OVERVIEW 214
FIGURE 33 PENUMBRA, INC.: COMPANY SNAPSHOT (2022) 215
10.1.6 MICROPORT SCIENTIFIC CORPORATION 217
TABLE 205 MICROPORT SCIENTIFIC CORPORATION: BUSINESS OVERVIEW 217
FIGURE 34 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2022) 218
10.1.7 BALT 221
TABLE 206 BALT: BUSINESS OVERVIEW 221
10.1.8 KANEKA CORPORATION 224
TABLE 207 KANEKA CORPORATION: BUSINESS OVERVIEW 224
FIGURE 35 KANEKA CORPORATION: COMPANY SNAPSHOT (2022) 225
TABLE 208 PRODUCT LAUNCHES 226
10.1.9 PHENOX GMBH 227
TABLE 209 PHENOX GMBH: BUSINESS OVERVIEW 227
10.1.10 ASAHI INTECC CO., LTD 229
TABLE 210 ASAHI INTECC CO., LTD.: BUSINESS OVERVIEW 229
FIGURE 36 ASAHI INTECC: COMPANY SNAPSHOT (2022) 229
10.1.11 PERFLOW MEDICAL LTD. 231
TABLE 211 PERFLOW MEDICAL LTD.: BUSINESS OVERVIEW 231
10.1.12 RAPID MEDICAL 233
TABLE 212 RAPID MEDICAL: BUSINESS OVERVIEW 233
10.1.13 CERUS ENDOVASCULAR INC. 235
TABLE 213 CERUS ENDOVASCULAR INC.: BUSINESS OVERVIEW 235
10.1.14 ACANDIS GMBH 237
TABLE 214 ACANDIS GMBH: BUSINESS OVERVIEW 237
TABLE 215 ACANDIS GMBH: PRODUCTS OFFERED 237
10.1.15 EVASC 239
TABLE 216 EVASC: BUSINESS OVERVIEW 239
10.1.16 SENSOME 240
TABLE 217 SENSOME: BUSINESS OVERVIEW 240
10.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 241
TABLE 218 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: BUSINESS OVERVIEW 241
FIGURE 37 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: COMPANY SNAPSHOT (2021) 242
10.1.18 IMPERATIVE CARE 244
TABLE 219 IMPERATIVE CARE: BUSINESS OVERVIEW 244
TABLE 220 IMPERATIVE CARE: PRODUCT LAUNCHES AND APPROVALS 245
10.1.19 MEDIKIT CO., LTD. 246
TABLE 221 MEDIKIT CO., LTD.: BUSINESS OVERVIEW 246
10.1.20 ZYLOX-TONBRIDGE MEDICAL CO., LTD. 247
TABLE 222 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: BUSINESS OVERVIEW 247
FIGURE 38 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: COMPANY SNAPSHOT (2021) 248
TABLE 223 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: PRODUCT LAUNCHES AND APPROVALS 249
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS 250
10.2.1 SILK ROAD MEDICAL, INC. 250
10.2.2 ARTIO MEDICAL, INC. 250
10.2.3 IVASCULAR 251
10.2.4 OXFORDENDOVASCULAR 251
10.2.5 NEUROVASC TECHNOLOGIES, INC. 252
11 APPENDIX 253
11.1 DISCUSSION GUIDE 253
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 257
11.3 CUSTOMIZATION OPTIONS 259
11.4 RELATED REPORTS 260
11.5 AUTHOR DETAILS 261

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 神経血管デバイスの世界市場予測（～2028）：病態別、エンドユーザー別、地域別(Neurovascular Devices Market by Disease Pathology (Cerebral Ameurysm (Embolic coils), Ischemic Stroke (Clot retrievers, Aspiration, Microcatheters), AVM (Liquid Embolic Agents)), End User (Hospitals), & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

神経血管デバイスの世界市場予測（～2028）：病態別、エンドユーザー別、地域別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp